Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer

This study tests whether combining two drugs — cadonilimab (an immunotherapy) and anlotinib (a drug that blocks tumor blood vessel growth) — is safe and effective for women with recurrent, metastatic, or persistent cervical cancer. This type of cancer has come back or spread after initial treatment, which makes it difficult to manage. **You may be eligible if...** - You are a woman aged 18–75 - You have cervical cancer (squamous cell, adenocarcinoma, or adenosquamous type) - Your cancer has come back, spread, or not responded to prior treatment - Your overall health is good (ECOG 0–1) - You have adequate organ function (blood, liver, kidney tests within range) **You may NOT be eligible if...** - You have active autoimmune disease - You have had prior anti-PD-1/PD-L1 immunotherapy or anlotinib - You are pregnant or breastfeeding - You have uncontrolled high blood pressure or serious heart problems Talk to your doctor to see if this trial is right for you.